Skip to main content
SpringerLink
Log in

Hylan G-F 20 Single-Injection Formulation

  • Adis Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Hylan G-F 20, a cross-linked hyaluronic acid derivative, is an elastoviscous, high-molecular-weight (average 6000 kDa) fluid with rheological properties similar to those of knee synovial fluid of healthy young individuals.

In a 26-week, randomized, double-blind, multi-centre study in patients with symptomatic primary osteoarthritis of the knee (n = 253), one intraarticular injection of hylan G-F 20 (single-injection formulation) into the target knee significantly relieved pain (as measured by the Western Ontario and McMaster Universities Osteoarthritis Index pain [WOMAC A] subscale), including pain while walking on a flat surface (as assessed by the WOMAC A1 subscore), compared with placebo.

Observer-reported disease status and patient-reported health status were also significantly improved in hylan G-F 20-treated patients compared with placebo-treated patients.

A single intra-articular injection of hylan G-F 20 was generally well tolerated, with an adverse event profile similar to that of placebo.

Repeat administration of hylan G-F 20 after 6 months had a similar tolerability profile to that of the initial injection. However, no patient who developed a target-knee adverse event after their first injection experienced such an event following their second injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dillon CF, Rasch EK, Gu Q, et al. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991–94. J Rheumatol 2006 Nov; 33(11): 2271–9

    PubMed  Google Scholar 

  2. Jordan JM, Helmick CG, Renner JB, et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol 2007 Jan; 34(1): 172–80

    PubMed  Google Scholar 

  3. Felsen DT, Naimark A, Anderson J, et al. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1987 Aug; 30(8): 914–8

    Article  Google Scholar 

  4. Knee osteoarthritis statistics. American Academy of Orthopedic Surgeons [online]. Available from URL: http://orthoinfo.aaos.org/topic.cfm?topic=A00399 [Accessed 2009 Aug 10]

  5. Arthritis types — overview: osteoarthritis. Centers for Disease Control and Prevention [online]. Available from URL: http://www.cdc.gov/arthritis/arthritis/osteoarthritis.htm [Accessed 2009 Aug 10]

  6. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 Sep; 43(9): 1905–15

    Google Scholar 

  7. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartilage 2008; 16: 137–62

    Article  CAS  Google Scholar 

  8. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology 2007; 44: 59–74

    PubMed  CAS  Google Scholar 

  9. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf 2000 Aug; 23(2): 115–30

    Article  PubMed  CAS  Google Scholar 

  10. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006 Apr 19;(2): CD005321

    Google Scholar 

  11. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clin Orthop Relat Res 2007 Feb; 455: 113–22

    Article  PubMed  Google Scholar 

  12. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 2007; 24(8): 629–42

    Article  PubMed  CAS  Google Scholar 

  13. Brzusek D, Petron D. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin 2008 Dec; 24(12): 3307–22

    Article  PubMed  CAS  Google Scholar 

  14. Wang C-T, Lin J, Chee-Jen C, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. J Bone Joint Surg 2004 Mar; 86A(3): 538–45

    Google Scholar 

  15. Conrozier T, Chevalier X. Long-term experience with hylan GF-20 in the treatment of knee osteoarthritis. Expert Opin Pharmacother 2008 Jul; 9(10): 1797–804

    Article  PubMed  CAS  Google Scholar 

  16. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multi-center trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthr Cartilage 1995 Dec; 3(4): 213–25

    Article  CAS  Google Scholar 

  17. Wobig M, Dickhut A, Maier R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998 May; 20(3): 410–23

    Article  PubMed  CAS  Google Scholar 

  18. Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthr Cartilage 2002 Jul; 10(7): 506–17

    Article  Google Scholar 

  19. Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg 2006 Jan; 19(1): 19–27

    PubMed  Google Scholar 

  20. Kemper F, Gebhardt U, Meng T, et al. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin 2005 Aug; 21(8): 1261–9

    Article  PubMed  CAS  Google Scholar 

  21. Caborn D, Rush J, Lanzer W. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004; 31: 333–43

    PubMed  CAS  Google Scholar 

  22. Raman R, Dutta A, Day N, et al. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee: a prospective randomized clinical trial. Knee 2008 Aug; 15(4): 318–24

    Article  PubMed  CAS  Google Scholar 

  23. Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 2007 Dec 15; 57(8): 1410–8

    Article  PubMed  Google Scholar 

  24. Cubukcu D, Ardic F, Karabulut N, et al. Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clin Rheumatol 2005 Aug; 24(4): 336–41

    Article  PubMed  CAS  Google Scholar 

  25. Karatay S, Kiziltunc A, Yildirim K, et al. Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clin Rheumatol 2005 Sep; 24(5): 497–501

    Article  PubMed  Google Scholar 

  26. Bagga H, Burkhardt D, Sambrook P, et al. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 2006 May; 33(5): 946–50

    PubMed  CAS  Google Scholar 

  27. Synvisc one™ (hylan G-F 20): information for prescribers. Ridgefield (NJ): Genzyme Biosurgery, a division of Genzyme Corporation, 2009 Mar 19

  28. Greenberg DD, Stoker A, Kane S, et al. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthr Cartilage 2006 Aug; 14(8): 814–22

    Article  CAS  Google Scholar 

  29. Shah RV, Ericksen JJ, Lacerte M. Interventions in chronic pain management: 2. New frontiers: invasive non-surgical interventions. Arch Phys Med Rehabil 2003 Mar; 84 (3 Suppl. 1): S39–44

    Article  PubMed  Google Scholar 

  30. Gomis A, Miralles A, Schmidt RF, et al. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain 2007 Jul; 130: 126–36

    Article  PubMed  CAS  Google Scholar 

  31. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hyland for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003; 5: 54–67

    Article  PubMed  CAS  Google Scholar 

  32. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002 Aug; 32(1): 10–37

    Article  PubMed  CAS  Google Scholar 

  33. Jackson DW, Simon TM. Intra-articular distribution and residence time of hylan A and B: as study in the goat knee. Osteoarthr Cartilage 2006; 14: 1248–57

    Article  CAS  Google Scholar 

  34. Larsen NE, Dursema H, Skrabut EM. Clearance kinetics of a single injection crosslinked hylan-based viscosupplement in a rabbit model [abstract no. 99]. Osteoarthr Cartilage 2007; 15(Suppl. C): e64

    Article  Google Scholar 

  35. Synvisc, solution for injection: data sheet. Auckland: Healthcare Logistics [online]. Available from URL: http://www.medsafe.govt.nz/Profs/Datasheet/s/Synviscinj.htm [Accessed 2009 Aug 28]

  36. Sakamoto T, Mizuno S, Miyazaki K, et al. Biological fate of sodium hyaluronate. Studies on distribution, metabolism and excretion of 14C-SPH in rabbits after intra-articular administration. Pharmacometrics 1984; 28(2): 375–87

    CAS  Google Scholar 

  37. Chevalier X, Jerosch J, Goupille P, et al. Single, intraarticular treatment with 6mL of hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multi-centre, double-blind, placebo-controlled trial. Ann Rheum Dis. Epub 2009 Mar 19

    Google Scholar 

  38. US Food and Drug Administration. Summary of safety and effectiveness data: hyaluronic acid, intraarticular (Synvisc one) [online]. Available from URL: http://www.accessda-ta.fda.gov/cdrh_docs/pdf/P940015S012b.pdf [Accessed 2009 Aug 19]

  39. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986 Aug; 29(8): 1039–49

    Article  PubMed  CAS  Google Scholar 

  40. Kellgren JH, Lawrence JS. Radiographic assessment of osteoarthritis. Ann Rheum Dis 1957; 16: 494–502

    Article  PubMed  CAS  Google Scholar 

  41. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartilage 2004; 12(5): 389–99

    Article  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: V. Goldberg, Department of Orthopaedic Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA; and D.D. Waddell, Louisiana State University Health Sciences Center — Department of Orthopedics, Orthopedic Specialists of Louisiana, Shreveport, Louisiana, USA.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Hylan G-F 20 Single-Injection Formulation. Drugs Aging 27, 77–85 (2010). https://doi.org/10.2165/11203900-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11203900-000000000-00000

Keywords

Search

Navigation